{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SKI-606&page=2", "query": { "intervention": "SKI-606", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 51, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SKI-606&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SKI-606&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T21:14:16.671Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02269267", "title": "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Chronic" ], "interventions": [ { "name": "Imatinib (Stopping their TKI)", "type": "DRUG" }, { "name": "Dasatinib (Stopping their TKI)", "type": "DRUG" }, { "name": "Nilotinib (Stopping their TKI)", "type": "DRUG" }, { "name": "Bosutinib (Stopping their TKI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2014-12-18", "completion_date": "2022-04-06", "has_results": true, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 16, "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New Lenox", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269267" }, { "nct_id": "NCT06423911", "title": "Study of Olverembatinib (HQP1351) in Patients With CML-CP", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloid Leukemia", "CML", "CML, Chronic Phase" ], "interventions": [ { "name": "olverembatinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascentage Pharma Group Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2024-02-05", "completion_date": "2028-07-10", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06423911" }, { "nct_id": "NCT07091019", "title": "A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myelogenous Leukemia - Chronic Phase" ], "interventions": [ { "name": "TKIs", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1000, "start_date": "2025-12-17", "completion_date": "2033-04-20", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Stockton, California • Torrance, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stockton", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07091019" }, { "nct_id": "NCT04971226", "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Asciminib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 405, "start_date": "2021-10-06", "completion_date": "2031-01-18", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 13, "location_summary": "Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971226" }, { "nct_id": "NCT07151820", "title": "A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia, Chronic Myeloid" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2546, "start_date": "2024-04-08", "completion_date": "2024-10-22", "has_results": false, "last_update_posted_date": "2025-09-03", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07151820" }, { "nct_id": "NCT00195260", "title": "Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "bosutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2004-10", "completion_date": "2007-11", "has_results": true, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 19, "location_summary": "Birmington, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more", "locations": [ { "city": "Birmington", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00195260" }, { "nct_id": "NCT03854903", "title": "WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "Hormone Receptor Positive Breast Cancer" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 19, "start_date": "2019-04-01", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03854903" }, { "nct_id": "NCT03045120", "title": "Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Phase Chronic Myeloid Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2017-07-19", "completion_date": "2022-06-20", "has_results": false, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 24, "location_summary": "Chicago, Illinois • Elk Grove Village, Illinois • Hoffman Estates, Illinois + 18 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Hoffman Estates", "state": "Illinois" }, { "city": "Lake Forest", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03045120" }, { "nct_id": "NCT04626024", "title": "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia", "Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission", "Chronic Myeloid Leukemia in Remission" ], "interventions": [ { "name": "Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal", "type": "OTHER" }, { "name": "Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-12-22", "completion_date": "2028-11-15", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 4, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04626024" }, { "nct_id": "NCT01025570", "title": "A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine, Bosutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2010-05", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-05-09", "last_synced_at": "2026-10-01T21:14:16.671Z", "location_count": 2, "location_summary": "San Francisco, California • Salt Lake City, Utah", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01025570" } ] }